Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
The current phase of work includes process optimization and scale-up manufacturing aimed at producing 50 grams of Onco's proprietary PNKP inhibitor, known as A83B4C63. This material will be used in preclinical studies, including in-vitro and in-vivo testing, and is intended to support regulatory preparations for an Investigational New Drug (IND) submission in the United States, which the Company plans on making this year. Dalton, a leading Canadian contract development and manufacturing organization (CDMO), brings deep technical expertise and regulatory compliance capabilities to the project.
In 2021, researchers from the University of Alberta published two peer-reviewed studies evaluating Onco-Innovations' nanoparticle-formulated PNKP inhibitor, A83B4C63, in preclinical models of colorectal cancer. The June study[1] demonstrated that treatment with the nanoparticle-encapsulated PNKP inhibitor significantly extended median survival in PTEN-deficient colorectal cancer-bearing mice to 60 days, compared to 23 days in untreated controls. The December study[2] found that combining the nanoparticle-formulated PNKP inhibitor with radiation therapy enhanced tumor growth delay in colorectal cancer models, without significant toxicity to healthy tissues. These findings support further development of the PNKP inhibitor as a targeted therapeutic approach in oncology.
"This marks an important inflection point in our development roadmap, as manufacturing now begins to generate the material necessary to support future preclinical evaluation. We are now taking another tangible step toward translating a novel scientific approach towards potential therapeutic development, setting the stage for the next critical phases ahead," stated Thomas O'Shaughnessy, CEO of the Company.
About Dalton Pharma ServicesDalton Pharma Services, established in 1986 and based in Toronto, Canada, is a Health Canada-approved and FDA-inspected GMP contract provider of integrated chemistry, drug development, and manufacturing services to the pharmaceutical and biotechnology industries. With over 35 years of experience, Dalton offers a comprehensive range of in-house services, including drug discovery, flow chemistry, formulation and process development, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing, and dosage form manufacturing. This integration at a single location enhances adaptability, flexibility, and cost-effectiveness, accelerating drug discovery and development programs. Dalton's commitment to quality, speed, and flexibility has been recognized with CMO Leadership Awards from Life Science Leader in 2016, 2017, and 2018 across categories such as Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.[3]
About Onco-Innovations LimitedOnco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,"Thomas O'Shaughnessy"Chief Executive Officer
For more information, please contact:Thomas O'ShaughnessyChief Executive OfficerTel: + 1 888 261 8055investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, including its PKNP Inhibitor Technology, the Company's ability to complete further preclinical or other research and development activities, and the Company's plans with respect to pursuing an IND, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies (including its PKNP Inhibitor Technology), the failure to submit an NDA or to pursue further regulatory or preclinical trials, the failure to receive regulatory approval in respect of its research and development activities, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[1] Sadat et al. A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer. J Control Release. 2021 Jun 10;334:335-352. doi:10.1016/j.jconrel.2021.04.034
[2] Sadat et al. Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage. Front Oncol. 2021 Dec 23;11:772920. doi: 10.3389/fonc.2021.772920
[3] https://www.dalton.com/pharmaceutical-manufacturing
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
These are the best Canadian wines under $40 — plus how to tell if a bottle is worth your cash
Plus wine insiders share the secrets to finding the best bottles at an affordable price point. Twenty years ago, asking for Canadian wine recommendations might have raised eyebrows. Today, sommeliers from Toronto to Tokyo are championing bottles from the Okanagan Valley and Prince Edward County. The transformation has been remarkable: What was once considered a novelty has evolved into one of the world's most dynamic wine scenes. The sweet spot for discovery? The under-$40 CAD range, where established producers offer genuine quality without the premium markup of their flagship bottles. Whether you're just beginning to explore Canadian wine or seeking exceptional value, here's how to shop smarter and drink better. If you're looking to switch from your current U.S.-produced bottle or just want to learn more about local Canadian wines, read on for everything you need to know. The golden rule for finding great wine in Canada: Producer over everything When it comes to Canadian wine, experts say quality varies far more by who makes the wine than what grape appears on the label. This is especially important when navigating a relatively young wine scene. "It's very much about producer," says Geoffrey Moss, one of only 400 Masters of Wine globally and an Okanagan, B.C.-based educator. Matthew Landry, sommelier and wine educator, puts it simply: "Always go for the entry-level from a top producer. Chances are, they know what they're doing." A $25 bottle from a respected winery will almost always outperform a $35 bottle from a mediocre one. Know your Canadian wine geography Canada's wine regions span three provinces that dominate quality production. Ontario, anchored by the Niagara Peninsula, produces elegant cool-climate wines. British Columbia's Okanagan Valley delivers both powerful reds and mineral-driven whites. Nova Scotia's emerging scene, particularly the Annapolis Valley, specializes in sparkling wines and aromatic whites. Within these broader regions, certain subzones are producing exceptional results. "The areas around Kelowna, particularly East Kelowna and South Kelowna Slopes, are producing mineral-driven cool climate reds and whites that really speak to the terroir," says Barbara Philip, category manager for BC Liquor. Terroir — the combination of soil, climate and geography that gives wine its sense of place — is increasingly evident in Canada's best bottles. "Vancouver Island, particularly the Cowichan Valley, is a region to keep a watch on for delicious pinot noir," Philip adds. Meanwhile, Prince Edward County has emerged as Ontario's answer to Burgundy, with limestone-rich soils producing exceptional pinot noir and Chardonnay. The insider's secret: Riesling rules Ask any wine professional to name the most undervalued Canadian grape, and riesling emerges as the unanimous answer. This represents perhaps the best opportunity for wine lovers seeking exceptional quality at modest prices. "Perhaps fortunately for riesling lovers, the grape is still misunderstood by a large segment of the population, which pulls down the price wineries can ask for these bottles," explains Landry. "Really high-end, chiselled riesling at the $35 price range is easy to find all across the country." Canadian riesling competes directly with Germany's finest expressions but often costs 30 per cent less. "You can buy some of the top rieslings across Canada, whether from Niagara or the Okanagan, which are truly world-class in quality," Moss adds. From a retail perspective, this insight holds especially true for dry styles. "The great rieslings, the dry styles especially, are still under the radar for many consumers," notes Philip. Decoding Canadian wine labels Canadian wine labels can be challenging to navigate, but understanding key indicators helps you shop more effectively. The most critical information often appears in small print. "The most critical thing to pay attention to is the source of the grapes," emphasizes Moss. "Are they grown in Canada or are they International-Canadian blends, which are largely composed of cheap imported bulk wine with little to no Canadian inputs?" Look for specific regional designations for the best chances of quality. For riesling specifically, alcohol content provides a sweetness clue if you're worried about finding a bottle that's simply too sugary. "For riesling, less than 11 per cent alcohol and you can expect some sweetness," explains Landry. Dry rieslings typically clock in at 12 per cent or higher. Beyond the classics: Exploring Canada's diverse wines While international grape varieties like Chardonnay and cabernet franc anchor many Canadian wine lists, exploring beyond these classics reveals exciting discoveries. Gamay, Burgundy's "other" red grape, produces exceptional results in Canadian conditions. "High-quality gamay can be found from terroir-driven producers like Niagara-based winemaker Thomas Bachelder, Jeff Moote of Divergence and Ilya Senchuk of Leaning Post," says Leah Spooner, a Toronto-based wine writer and communicator. But don't underestimate Canada's potential for reds in general. "We make every type," says Landry, "from powerful Bordeaux blends and savoury syrah in the South Okanagan, to elegant pinot and gamay on the Niagara Escarpment." Where to find the best bottles of Canadian wine While government liquor stores carry many Canadian wines, the most exciting discoveries often require more targeted hunting, experts say. "The majority of the best Canadian wines can only be purchased winery-direct because they are made with the precision that can only be derived from careful, small-batch winemaking," explains Spooner. "Get on the wine trail to see the true quality of Canadian wine." This means building relationships with independent wine shops, joining winery mailing lists and planning visits to wine regions. Best Canadian wines under $40 It's an interesting time to be a first-timer exploring Canadian wine, particularly from British Columbia. A devastating January freeze reduced the province's 2024 grape crop to less than five per cent of normal production. The B.C. government temporarily allowed wineries to source grapes from elsewhere in the country, or beyond the border in Washington, Oregon and California, creating "replacement wines" that showcase producer skill despite extraordinary circumstances. If you're looking for some of the best Canadian wines under $40, here are some recommendations. Canadian white wine Hester Creek Columbia Valley Viognier 2024, $24 Leaning Post Chardonnay 2023, $30 Roche Pinot Gris 'Artist' 2024. $27 Stratus Chardonnay 2021, $35 Tantalus Riesling 2024, $28 Tawse Sketches Riesling 2022, $20 Canadian red wine Bachelder Les Villages Gamay Noir Niagara 2023, $26 Blue Mountain Gamay Noir 2023, $26 Burrowing Owl Syrah 2022, $35 Road 13 Select Harvest Seventy-Four K 2021, $28 Ursa Major Fan Fiction 2024, $28 Canadian sparkling wine Benjamin Bridge NV Brut, $27 Fitzpatrick FITZ Brut 2020, $37
Forbes
2 hours ago
- Forbes
New NHL CBA Will Make It Tougher For Canadian Teams To Compete
TORONTO, ON - APRIL 27: Auston Matthews #34 of the Toronto Maple Leafs sets for a face-off against ... More the Boston Bruins during the second period in Game Four of the First Round of the 2024 Stanley Cup Playoffs at Scotiabank Arena on April 27, 2024 in Toronto, Ontario, Canada. (Photo by Kevin Sousa/NHLI via Getty Images) It was already tough for NHL teams in Canada to compete. Taxes are high, the weather isn't great and the media scrutiny is intense (just ask Mitch Marner). Well, the new NHL CBA is about to make things a bit more challenging for Canadian teams. The issue relates to taxes. Under the old CBA, all of a player's contract could be comprised of signing bonuses except for the CBA mandated yearly minimum salary. That has changed. The new CBA limits bonuses to 60% of a contract. Why does this matter? The Canadian tax on signing bonuses for non-residents of Canada is limited to 15%, with the player then paying the balance owing at the prevailing tax rate in his home state in the United States. So while a player who claims to be a resident of a U.S. state pays taxes in both Canada and the U.S., the combined tax savings is significant, potentially saving the player millions of dollars over the term of the contract. So to minimize the tax burden, some players on Canadian teams structure their contracts primarily by way of signing bonuses knowing those bonuses will only be taxed at 15% in Canada. That's why you sometimes see a player sign a deal with the CBA base salary of $775,000 and the other $10 million in signing bonuses. Taxes, taxes, taxes. Toronto Maple Leafs captain Auston Matthew signed a 4 year/$53,000,000 with $49,650,000 in signing bonuses. By structuring the contract with 94% in signing bonuses, Arizona resident Matthews stands to enjoy a substantial tax savings. On his last deal alone, Matthews saved around $4 million in taxes across his 5 year deal worth $58,201,250. MONTREAL, CANADA - FEBRUARY 3: Carey Price #31 of the Montreal Canadiens makes a pad save on the ... More puck on an attempt by Daniel Alfredsson #11 of the Ottawa Senators during the NHL game at the Bell Centre on February 3, 2013 in Montreal, Quebec, Canada. The Canadiens defeated the Senators 2-1. (Photo by) Matthews isn't the only player that has signed bonus laden contracts with a Canadian team to diminish the tax impact. Carey Price's contract has $70 million of the $84 million allocated to signing bonuses, which amounts to 84% of the total value of the contract. On his $122 million deal, 93% of Leon Draisaitl's contract is signing bonuses. And 75% of William Nylander's contract is comprised of signing bonuses. The money adds up quickly. With players having finite careers and finite earning potential, saving as much money as possible matters. And now there can be as much as an additional 35% of a player's income exposed to the very high Canadian tax rates. With the Canadiens, Leafs, Senators and Canucks leading the league in income tax rates, and with all seven Canadian teams in the top eleven in the NHL, things just got a bit more complicated for Canadian teams. It's tough enough with these teams competing against teams in tax free states like Florida, Tennessee, Nevada and Texas. And now, a relief valve for Canadian teams has been partially closed.
Business Insider
4 hours ago
- Business Insider
Upcoming Stock Splits This Week (July 28 to August 1)
These are the upcoming stock splits for the week of July 28 to August 1, based on TipRanks' Stock Splits Calendar. A stock split is a corporate play that boosts the number of shares in circulation by handing out extras to existing shareholders, without changing the company's overall value. This reduces the price per share, making the stock more affordable and often more appealing to retail investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. But not all splits are about broadening appeal. Some companies flip the script with a reverse stock split, consolidating shares to boost the share price while shrinking the total share count. The company's market cap stays the same, but the higher price tag often helps meet listing standards like Nasdaq's minimum price rule, warding off the threat of delisting. Whether the goal is to court investors or stay in the game, these corporate maneuvers often send signals that smart traders are quick to pick up on. Let's take a look at the upcoming stock splits for the week. ChargePoint Holdings (CHPT) – ChargePoint is an electric vehicle (EV) charging infrastructure provider operating an extensive network of chargers and connected services. On July 9, ChargePoint announced a 1‑for‑20 reverse stock split scheduled to become effective on July 28. The split is intended to increase the per-share price and regain compliance with NYSE's minimum bid price requirement, after trading below the $1.00 threshold since January 2025. FOXO Technologies (FOXO) – Developing advanced payment-processing platforms for the dental and medical industries, FOXO is taking strategic action to stay compliant with NYSE American listing standards. On July 17, the board approved a 1‑for‑1.99 reverse stock split effective on July 27, with trading on a split‑adjusted basis starting July 28. Mersana Therapeutics (MRSN) – Mersana is a clinical-stage biotech developing antibody‑drug conjugates (ADCs) targeting cancer. On July 24, it announced a 1‑for‑25 reverse stock split, effective before market open on July 28. The split seeks to increase per‑share price to regain Nasdaq Global Select listing compliance after prolonged depressed stock price. Ikena Oncology (IKNA) – Ikena Oncology, am immuno‑oncology biotech company, received shareholder approval on July 15 for a 1-for-12 reverse stock split, to be implemented at the start of trading on July 28 – the same day it merges with Inmagene Biopharmaceuticals. Upon closing, the combined company will be rebranded as ImageneBio and begin trading on Nasdaq under the ticker symbol IMA. AgriFORCE Growing Systems (AGRI) – AgriFORCE Growing Systems, a Canada-based ag-tech and food systems company listed in the U.S., is going through a 1-for-9 reverse stock split. Shareholders gave the green light back on June 6, and the move will officially take effect when markets opened on July 28. The goal here is to get the share price back above Nasdaq's $1.00 minimum and stay in compliance with listing rules. Velo3D, Inc. (VLDX) – Velo3D, a leading innovator in metal 3D printing technology, is making a move to reposition itself in the market. On July 25, the company announced a 1-for-15 reverse stock split, set to take effect at the start of trading on July 28. To mark the change, Velo3D shares will temporarily trade under the ticker symbol VLDXD for 20 sessions before reverting back to VLDX. Senmiao Technology (AIHS) – Senmiao Technology, a U.S.-listed fintech and auto-finance company based in China, is streamlining its stock structure with a 1-for-10 reverse split. Announced on July 24, and set to take effect on July 29, the move aims to lift its share price to meet Nasdaq's listing standards. Silexion Therapeutics (SLXN) – Israel-based Silexion Therapeutics is a clinical-stage biotechnology company focused on developing personalized cancer vaccines and immuno-oncology therapies. On July 16, Silexion announced a 1-for-15 reverse stock split of its common shares, effective after market close on July 28, with trading on a split-adjusted basis beginning July 29. The reverse split is intended to boost the stock price and regain compliance with Nasdaq's minimum bid price requirement for continued listing. NaaS Technology (NAAS) – NaaS Technology is a China-based provider of EV charging services and software, listed on the Nasdaq. On July 14, the company announced a 1-for-4 reverse ADS split set to take effect on or about July 30. The move aims to lift the ADS price, ensure compliance with Nasdaq's minimum bid requirement, and strengthen its appeal to investors. Biodexa Pharmaceuticals (BDRX) – Biodexa Pharmaceuticals is a UK-based clinical-stage biotechnology company focused on developing treatments for diseases with unmet medical needs, including a Phase 3 trial for familial adenomatous polyposis and a Phase 2a trial for type 1 diabetes. On July 15, the company announced a 1-for-10 reverse ADR split, effective July 31. The goal is to raise the ADR trading price to meet Nasdaq's $1.00 minimum bid price requirement. Yoshiharu Global (YOSH) – Yoshiharu Global is a restaurant operator specializing in Japanese ramen and rolls, primarily located in Southern California and Nevada. On July 18, the board and shareholders approved a 4-for-1 forward stock split, record date July 28, with the additional shares distributed after market close on July 30, and trading on a post-split basis starting July 31. The aim is to increase stock liquidity and investor accessibility, making the shares more appealing to retail investors. TipRanks Stock Splits Calendar.
